Bhubaneswar: In view of possible third wave of COVID-19 that is assumed to affect children, the All India Institute of Medical Sciences (AIIMS) Delhi will begin clinical trials of Bharat Biotech’s Covaxin on 6-12 age group from tomorrow.
The clinical trials will be conducted to evaluate the safety of Covaxin, India’s first indigenous COVID jab, on children at various sites including AIIMS Delhi, AIIMS Patna and Meditrina Institute of Medical Sciences, Nagpur .
The premier medical institution has recently completed the clinical trials of Covaxin on 12-18 age group. The trial of the vaccine will be conducted on 2-6 age group after completion of clinical trial for 6-12 age group.
The process for clinical trial of Covaxin on children aged between 2 and 18 had started at AIIMS Delhi on June 7.
Currently, Covaxin is being used on adults in ongoing COVID-19 vaccination drive.